(RS,SR)-N-[2-(4-carbomethoxyphenyl)-1-methylethyl]-2-hydroxy-2-phenylethanamine | 96788-25-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (RS,SR)-N-[2-(4-carbomethoxyphenyl)-1-methylethyl]-2-hydroxy-2-phenylethanamine
• 英文别名: N-[2-(4-carbomethoxyphenyl)-1-methylethyl]-2'-hydroxy-2'-phenylethanamine；N-[2-(4-carbomethoxyphenyl)-1-methylethyl]-2-hydroxy-2-phenylethylamine；N-(2-[4-Carbomethoxyphenyl]-1-methylethyl)-2-hydroxy-2-phenylethanamine；methyl 4-[2-[(2-hydroxy-2-phenylethyl)amino]propyl]benzoate
• CAS: 96788-25-9
• 化学式: C₁₉H₂₃NO₃
• 分子量: 313.397
• InChiKey: HGAQACVANZGWKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (RS,SR)-N-[2-(4-carbomethoxyphenyl)-1-methylethyl]-2-hydroxy-2-phenylethanamine 以 四氢呋喃 为溶剂， 生成 N-[2-(4-Hydroxymethylphenyl)-1-methylethyl]-2'-hydroxy-2'-phenylethanamine
  参考文献：
  名称：

  Secondary amines, their preparation and use in pharmaceutical

  摘要：

  具有以下化学式的化合物：##STR1## 其中R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5、Y和X的定义如下，对于降低异常高血糖和血脂水平，治疗肥胖或高血糖是有用的。

  公开号：

  US04396627A1
• 作为产物：
  描述：

  4-(2-氧代丙基)苯甲酸甲酯 、 2-氨基-1-苯乙醇 在 sodium borohydrid 作用下， 以 正己烷 、 水 、 苯 为溶剂， 生成 (RS,SR)-N-[2-(4-carbomethoxyphenyl)-1-methylethyl]-2-hydroxy-2-phenylethanamine
  参考文献：
  名称：

  Secondary amines, their preparation and use in pharmaceutical

  摘要：

  公式（II）的化合物：##STR1##及其药用可接受的盐，其中R.sub.1是氢、氟或氯原子或羟基、羟甲基、甲基、甲氧基、氨基、甲酰胺基、乙酰胺基、甲磺酰胺基、硝基、苄氧基、甲磺酰甲基、脲基、三氟甲基或对甲氧基苄氨基基团；R.sub.2是氢、氟或氯原子或羟基；R.sub.3是氢或氯原子或羟基；R.sub.4是羧酸基或其盐、酯或酰胺；R.sub.5是氢、氯或氟原子或甲基、甲氧基或羟基或羧酸基或其盐、酯或酰胺；R.sub.6是氢原子或甲基或丙基基团；X是氧原子或键；Y是最多含有6个碳原子的烷基基团或键，已发现具有抗肥胖和/或抗高血糖活性。

  公开号：

  US04478849A1

文献信息

• Phenylethanolamine analog active compounds for the treatment of
  申请人：Sanofi

  公开号：US05002946A1

  公开（公告）日：1991-03-26

  Phenylethanolamine analog active compounds, optionally substituted on the phenyl group with an halogen atom or with an alkyl or trifluoromethyl group and substituted on the amino group with a phenylalkyl or phenoxy alkyl group optionally substituted on the benzene ring, are used for the treatment and/or prophylaxis of gastrointestinal diseases associated with a smooth muscle contraction.

  苯乙醇胺类似物活性化合物，可选地在苯基上用卤素原子或烷基或三氟甲基基团取代，并在氨基上用苯基烷基或苯氧基烷基取代，可选地在苯环上取代，用于治疗和/或预防与平滑肌收缩相关的胃肠道疾病。
• Tertiary amines
  申请人：Beecham Group plc

  公开号：US04803293A1

  公开（公告）日：1989-02-07

  Compounds of formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, in which R.sup.1 is hydrogen, halogen, or trifluoromethyl, R.sup.2 is hydrogen or halogen, R.sup.3 is hydroxyl, C.sub.1-6 alkoxy or ##STR2## where R.sup.8 and R.sup.9 are each hydrogen or C.sub.1-6 alkyl; R.sup.4 is hydrogen or C.sub.1-6 alkyl; R.sup.5 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkyl optionally substituted by hydroxy; cyano, C.sub.1-6 alkenyl or C.sub.1-6 alkynyl optionally substituted by carboxy or esters and amides thereof, phenyl, C.sub.1-6 alkyl phenyl or a group ##STR3## wherein R.sup.12 and R.sup.13 are each hydrogen or C.sub.1-6 alkyl or together, along with the nitrogen to which they are attached, form a 5- or 6-membered ring and m is 1 or 2; R.sup.6 is hydrogen or methyl: R.sup.7 is --O(CH.sub.2).sub.a CO.sub.2 H, --O(CH.sub.2).sub.b M, --CO.sub.2 H; or amide thereof in which a is an integer from 1 to 6, b is an integer from 2 to 7, and M is hydroxy, C.sub.1-6 alkoxy or ##STR4## in which R.sup.10 and R.sup.11 are each hydrogen or C.sub.1-6 alkyl or ##STR5## together form a five or six membered ring; and n is 1 or 2; with the proviso that when n is 2 and R.sup.1, R.sup.2, R.sup.4 and R.sup.6 are each hydrogen and R.sup.3 is hydroxyl, R.sup.5 is not hydroxymethyl or 1-hydroxy ethyl when R.sup.7 is CONH.sub.2 ; processes for preparing such compounds and their use in medicine.

  化学式(I)的化合物：##STR1##或其药学上可接受的盐，其中R.sup.1是氢，卤素或三氟甲基，R.sup.2是氢或卤素，R.sup.3是羟基，C.sub.1-6烷氧基或##STR2##其中R.sup.8和R.sup.9分别是氢或C.sub.1-6烷基; R.sup.4是氢或C.sub.1-6烷基; R.sup.5是氢，C.sub.1-6烷基，C.sub.1-6烷基可选择地被羟基取代;氰基，C.sub.1-6烯基或C.sub.1-6炔基，可选择地被羧基或其酯和酰胺取代，苯基，C.sub.1-6烷基苯基或##STR3##其中R.sup.12和R.sup.13分别是氢或C.sub.1-6烷基，或连同它们所连接的氮一起形成5-或6-成员环，m为1或2; R.sup.6是氢或甲基：R.sup.7是--O(CH.sub.2).sub.a CO.sub.2 H，--O(CH.sub.2).sub.b M，--CO.sub.2 H;或其酰胺，其中a是1到6的整数，b是2到7的整数，M是羟基，C.sub.1-6烷氧基或##STR4##其中R.sup.10和R.sup.11分别是氢或C.sub.1-6烷基或##STR5##共同形成五元或六元环; n为1或2；但当n为2且R.sup.1，R.sup.2，R.sup.4和R.sup.6分别为氢，而R.sup.3为羟基时，当R.sup.7为CONH.sub.2时，R.sup.5不是羟甲基或1-羟乙基；制备这种化合物的方法以及它们在医学上的用途。
• Secondary amines, their preparation, pharmaceutical compositions containing them and their use
  申请人：BEECHAM GROUP PLC

  公开号：EP0006735A1

  公开（公告）日：1980-01-09

  The compounds of the formula (II): and their pharmaceutically acceptable salts wherein R, is a hydrogen, fluorine or chlorine atom or a hydroxyl, hydroxymethyl. methyl, methoxy, amino. formamido. acetamido. methylsulphonylamido, nitro, benzyloxy, methyisuiphonylmethyl. ureido, trifluoromethyl or p-methoxybenrylamino group; R2 is a hydrogen, fluorine or chlorine atom or a hydroxyi group; R3 is a hydrogen or chlorine atom or a hydroxyl group; R4 is a carboxylic acid group or a salt, ester or amide thereof; R5 is a hydrogen. chlaine or fluorine atom or a methyl, methoxyl or hydroxyl group or a carboxylic acid group or a salt, ester or amide thereof: R5 is a hydrogen atom or a methyl, or propyl group; X is an oxygen atom or a bond: and Y is an alkylene group of up to 6 carbon atoms or a bond have been found to possess anti-obesity and/ or antihypergtycaemic activity.

  分子式为（II）的化合物及其药用盐，其中R为氢、氟或氯原子，或羟基、羟甲基、甲基、甲氧基、氨基、甲酰胺基、乙酰胺基、甲磺酰胺基、硝基、苄氧基、甲基磺酰甲基、脲基、三氟甲基或对甲氧基苯基氨基基团；R2为氢、氟或氯原子，或羟基基团；R3为氢或氯原子，或羟基基团；R4为羧酸基团或其盐、酯或酰胺；R5为氢、氯或氟原子，或甲基、甲氧基或羟基基团，或羧酸基团或其盐、酯或酰胺；R6为氢原子或甲基、丙基基团；X为氧原子或键；Y为长度不超过6个碳原子的烷基团或键，已被发现具有抗肥胖和/或抗高血糖活性。
• Secondary amines, their preparation and use in pharmaceutical compositions
  申请人：BEECHAM GROUP PLC

  公开号：EP0021636A1

  公开（公告）日：1981-01-07

  The compounds of formula (II); in which R1 is a hydrogen, fluorine, chlorine or bromine atom or a hydroxyl, hydroxymethyl, methyl, methoxyl, amino, formamido, acetamido, methylsulphonylamido, nitro, benzyloxy, methylsulphonylmethyl, ureido, trifluoromethyl or p-methoxybenzylamino group; R2 is a hydrogen, fluorine, chlorine or bromine atom or a hydroxyl group; R3 is a hydrogen, chlorine or bromine atom or a hydroxyl group, R4 is an alkyl group of 1 to 10 carbon atoms substituted by a hydroxyl, lower alkoxyl, oxo, lower acyloxy or OCH2CO2H group or lower alkyl esterthereof; R5 is a hydrogen, chlorine orfluorine atom of a methyl, methoxyl or hydroxyl group or a carboxylic acid group or a salt, ester or amide thereof; R6 is a hydrogen atom or a methyl, ethyl or propyl group; R7 is a hydrogen atom or a methyl, ethyl or propyl group; X is an oxygen atom or a bond; and Y is an alkylene group of up to 6 carbon atoms or a bond, have been found to possess anti-obesity and/or anti-hyperglycaemic activity. They are prepared by for analogous compounds usual methods.

  式(II)化合物； 其中 R1 是氢、氟、氯或溴原子或羟基、羟甲基、甲基、甲氧基、氨基、甲酰氨基、乙酰氨基、甲磺酰氨基、硝基、苄氧基、甲磺酰甲基、脲基、三氟甲基或对甲氧基苄基氨基；R2 是氢、氟、氯或溴原子或羟基； R3 是氢、氯或溴原子或羟基， R4 是被羟基、低级烷氧基、氧代、低级酰氧基或 OCH2CO2H 基团或其低级烷基酯取代的 1 至 10 个碳原子的烷基；R5 是甲基、甲氧基或羟基或羧基或其盐、酯或酰胺的氢、氯或氟原子；R6 是氢原子或甲基、乙基或丙基；R7 是氢原子或甲基、乙基或丙基；X 是氧原子或键；Y 是最多 6 个碳原子的亚烷基或键。它们是通过类似化合物的通常方法制备的。
• Use of aryl ethanol amine derivatives in the treatment of atherosclerosis
  申请人：BEECHAM GROUP PLC

  公开号：EP0244062A2

  公开（公告）日：1987-11-04

  A method for increasing high-density lipoprotein (HDL) cholesterol concentration and/or decreasing total cholesterol concentration and/or decreasing triglyceride concentration in human blood serum, which method comprises the administration of an effective, non-toxic amount of a compound selected from the list consisting of compounds of the, herein defined, formulae: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), (XXI), (XXII), (XXIII), (XXIV), (XXV), (XXVI), (XXVII), (XXVIII), (XXIX) and (XXX); or, where appropriate, a pharmaceutically acceptable salt, ester or amide thereof.

  一种提高人体血清中高密度脂蛋白（HDL）胆固醇浓度和/或降低总胆固醇浓度和/或甘油三酯浓度的方法，该方法包括施用有效、无毒量的化合物，该化合物选自由本文定义的式组成的清单中的化合物：(i), (ii), (iii), (iv), (v), (vi), (vii), (viii), (ix), (x), (xi), (xii), (xiii), (xiv), (xv), (xvi), (xvii)、(XVIII), (XIX), (XX), (XXI), (XXII), (XXIII), (XXIV), (XXV), (XXVI), (XXVII), (XXVIII), (XXIX) 及 (XXX)；或适当情况下，其药学上可接受的盐、酯或酰胺。